Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Amgen (AMGN) closed at $187.10, marking a -1.57% move from the previous day. This move lagged the S&P 500's daily gain of 0.01%. Elsewhere, the Dow gained 0.35%, while the tech-heavy Nasdaq added 0.45%.
Coming into today, shares of the world's largest biotech drugmaker had lost 2.48% in the past month. In that same time, the Medical sector lost 5.57%, while the S&P 500 lost 7.29%.
AMGN will be looking to display strength as it nears its next earnings release, which is expected to be February 7, 2019. In that report, analysts expect AMGN to post earnings of $3.25 per share. This would mark year-over-year growth of 12.46%. Meanwhile, our latest consensus estimate is calling for revenue of $5.86 billion, up 1.03% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $14.24 per share and revenue of $23.34 billion, which would represent changes of +13.2% and +2.13%, respectively, from the prior year.
Any recent changes to analyst estimates for AMGN should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. AMGN is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that AMGN has a Forward P/E ratio of 13.35 right now. For comparison, its industry has an average Forward P/E of 21.42, which means AMGN is trading at a discount to the group.
Also, we should mention that AMGN has a PEG ratio of 1.97. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.46 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 69, putting it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amgen Inc. (AMGN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
